Latest HS2 sector trade
$900.6BReported global valueHS2 sector corridor intelligence
Pharmaceutical products
trade corridors
HS2 30 (Pharmaceutical products) · leading exporter-to-importer routes
Explore reported trade routes for HS2 30 (Pharmaceutical products), ranked by the latest trade value and paired with three-year growth, HS6 coverage, distance, and FTA context.
The route picture at a glanceLatest reported year · 2024
HS2 corridors shown
25Leading sector routesHS6 products in sector
43Classifications inside HS2Top five route share
14.3%Of latest HS2 sector tradeLatest reported year
2,024HS2 30 (Pharmaceutical products) coverageThe HS2 30 (Pharmaceutical products) corridor read
Ireland to USA, Puerto Rico and US Virgin Islands leads reported Pharmaceutical products trade routes.
HS2 30 (Pharmaceutical products) trade is distributed across the displayed exporter-to-importer relationships, with the largest lanes separated from the fastest-growing ones for clearer research. Read the HS2 30 (Pharmaceutical products) overview ↗
Leading route$41.6B+8.7% three-year growth
Top HS2 30 (Pharmaceutical products) corridors
Where HS2 30 (Pharmaceutical products) trade moves
These are the leading exporter-to-importer routes for HS2 30 (Pharmaceutical products). Growth and access are supporting context, not forecasts or tariff recommendations. Review the data sources ↗
HS2 30 (Pharmaceutical products) exporter-to-importer relationshipsTop 25 by value
| Rank | Exporter | Importer | Trade value | 3-year growth | Market share | HS6 products | Distance | FTA |
|---|---|---|---|---|---|---|---|---|
| 1 | IrelandIRL | USA, Puerto Rico and US Virgin IslandsUSA | $41.6B | +8.7% | 4.6% | 33 | 5,129 km | Not reported |
| 2 | Switzerland, LiechtensteinCHE | USA, Puerto Rico and US Virgin IslandsUSA | $28.4B | +1.3% | 3.2% | 31 | 6,339 km | Not reported |
| 3 | GermanyDEU | USA, Puerto Rico and US Virgin IslandsUSA | $23.8B | +2.7% | 2.6% | 35 | 6,402 km | Not reported |
| 4 | SloveniaSVN | Switzerland, LiechtensteinCHE | $20.4B | +82.9% | 2.3% | 19 | 481 km | Reported |
| 5 | BelgiumBEL | USA, Puerto Rico and US Virgin IslandsUSA | $14.9B | +11.8% | 1.7% | 35 | 5,904 km | Not reported |
| 6 | ItalyITA | USA, Puerto Rico and US Virgin IslandsUSA | $12.4B | +29.8% | 1.4% | 36 | 6,907 km | Not reported |
| 7 | SingaporeSGP | USA, Puerto Rico and US Virgin IslandsUSA | $11.6B | +36.4% | 1.3% | 26 | 15,347 km | Reported |
| 8 | Switzerland, LiechtensteinCHE | GermanyDEU | $11.5B | -0.4% | 1.3% | 37 | 674 km | Reported |
| 9 | USA, Puerto Rico and US Virgin IslandsUSA | GermanyDEU | $11.2B | +10.3% | 1.2% | 35 | 6,402 km | Not reported |
| 10 | IndiaIND | USA, Puerto Rico and US Virgin IslandsUSA | $10.7B | +10.8% | 1.2% | 37 | 11,771 km | Not reported |
| 11 | IrelandIRL | BelgiumBEL | $10.4B | -6.9% | 1.2% | 28 | 776 km | Reported |
| 12 | GermanyDEU | Switzerland, LiechtensteinCHE | $10.2B | +0.4% | 1.1% | 39 | 674 km | Reported |
| 13 | IrelandIRL | NetherlandsNLD | $10.2B | +53% | 1.1% | 36 | 757 km | Reported |
| 14 | ItalyITA | Switzerland, LiechtensteinCHE | $9.1B | +39.7% | 1% | 30 | 684 km | Reported |
| 15 | CanadaCAN | USA, Puerto Rico and US Virgin IslandsUSA | $8.3B | +8.6% | 0.9% | 37 | 556 km | Reported |
| 16 | GermanyDEU | NetherlandsNLD | $8.0B | +1% | 0.9% | 37 | 579 km | Reported |
| 17 | IrelandIRL | GermanyDEU | $8.0B | +0.1% | 0.9% | 30 | 1,321 km | Reported |
| 18 | Switzerland, LiechtensteinCHE | SloveniaSVN | $7.9B | +20.8% | 0.9% | 27 | 481 km | Reported |
| 19 | USA, Puerto Rico and US Virgin IslandsUSA | JapanJPN | $7.8B | +3.6% | 0.9% | 31 | 10,872 km | Not reported |
| 20 | United KingdomGBR | USA, Puerto Rico and US Virgin IslandsUSA | $7.5B | +10.3% | 0.8% | 38 | 5,585 km | Not reported |
| 21 | ItalyITA | BelgiumBEL | $7.3B | +0.8% | 0.8% | 30 | 1,174 km | Reported |
| 22 | USA, Puerto Rico and US Virgin IslandsUSA | ChinaCHN | $6.6B | +1.4% | 0.7% | 35 | 11,883 km | Not reported |
| 23 | NetherlandsNLD | GermanyDEU | $6.5B | -7.4% | 0.7% | 37 | 579 km | Reported |
| 24 | ChinaCHN | USA, Puerto Rico and US Virgin IslandsUSA | $6.3B | +25.3% | 0.7% | 34 | 11,883 km | Not reported |
| 25 | USA, Puerto Rico and US Virgin IslandsUSA | CanadaCAN | $6.2B | -6.5% | 0.7% | 40 | 556 km | Reported |
Movement to watch
Growth leaders for HS2 30 (Pharmaceutical products)
The strongest three-year growth rates are starting points for investigation. Check the underlying value and route conditions together. Read the methodology ↗
Slovenia to Switzerland, Liechtenstein+82.9% growth · $20.4B latest value · 2.3% share
Ireland to Netherlands+53% growth · $10.2B latest value · 1.1% share
Italy to Switzerland, Liechtenstein+39.7% growth · $9.1B latest value · 1% share
Singapore to USA, Puerto Rico and US Virgin Islands+36.4% growth · $11.6B latest value · 1.3% share
Italy to USA, Puerto Rico and US Virgin Islands+29.8% growth · $12.4B latest value · 1.4% share
Access comparison
Reported FTA context across HS2 30 (Pharmaceutical products) routes
Compare route value where a reported free-trade agreement indicator is available. Missing access context remains unavailable. Check coverage ↗
FTA reported
$135.4B
14 displayed corridors with average three-year growth of +15.9%.
FTA not reported
$171.3B
11 displayed corridors with average three-year growth of +10.5%.
How to read this view
How to read the HS2 30 (Pharmaceutical products) corridor view
Trade value identifies observed scale. Growth shows change over the available comparison period. Distance, FTA status, and product counts provide supporting route context. See how indicators are calculated ↗
Data source
OECD trade statistics with CEPII context
OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-28). OECD BIMTS is the primary trade series for this view. Supporting bilateral trade context uses CEPII BACI bilateral trade flows (202601) under Etalab 2.0 Open Licence. Yugalinks presents derived views of reported observations and calculated indicators. Data terms: OECD Terms & Conditions.